Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 conventional dendritic cells.

The use of immunotherapy to treat patients with myelodysplastic syndromes (MDS) shows promise but is limited by our incomplete understanding of the immunologic milieu. In solid tumors, CD141 conventional dendritic cells (CD141 cDCs) are necessary for antitumor immunosurveillance and the response to immunotherapy. Here, we found that CD141 cDCs are reduced in MDS bone marrow and based on the premise established in solid tumors, we hypothesized that reduced numbers of CD141 cDCs are associated with inferior overall survival in MDS patients.